Galiximab: a review

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Horner MJ, Ries LAG, Krapcho M, , editors, SEER Cancer Statistics Review, 1975 – 2006. National Cancer Institute. Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009
   Google Scholar
• Ries LAG, Melbert D, Krapcho M, , editors, SEER Cancer Statistics Review, 1975 – 2005. National Cancer Institute. Bethesda, MD; 2008. Available from: http://seer.cancer.gov/csr/1975_2005/
   Google Scholar
• Cancer Trends Progress Report (http://progressreport.cancer.gov), in 2004 dollars, based on methods described in Medical Care 2002;40(Suppl 8):IV-104-17.
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Morrison SL, Johnson MJ, Herzenberg LA, Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984;81:6851-5
   PubMed Web of Science ®Google Scholar
• Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51
   PubMedGoogle Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-8
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43
   PubMed Web of Science ®Google Scholar
• Foran JM, Gupta RK, Cunningham D, A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000;109:81-8
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Piro LD, White CA, Grillo-Lopez AJ, Extended rituximab (anti- CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-61
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Gallagher CJ, Gregory WM, Jones AE, Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4(10):1470-80
   PubMed Web of Science ®Google Scholar
• Horning SJ Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20(5 Suppl 5):75-88
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, Follicular lymphoma international prognostic index. Blood 2004;104 (5):1258-65
   PubMed Web of Science ®Google Scholar
• Boussiotis VA, Freedman AS, Nadler LM. Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol 1999;36(2):209-16
   PubMed Web of Science ®Google Scholar
• Johnson PWM, Rohatiner AZS, Whelan JS, Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13(1):140-7
   PubMed Web of Science ®Google Scholar
• McLaughlin P. Progress and promise in the treatment of indolent lymphomas. Oncologist 2002;7(3):217-25
   PubMed Web of Science ®Google Scholar
• Rohatiner AZS, Price CGA, Amott S, MyeIoablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Ann Oncol 1991;2(Suppl Z):147-50
   PubMedGoogle Scholar
• Cabanillas F, Hagemeister FB, McLaughlin P, Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987;5(3):407-12
   PubMed Web of Science ®Google Scholar
• Niitsu N, Umeda M. Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy. Eur J Haematol 1996;57(4):320-4
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71(1):117-22
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12(6):1169-76
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Koryzna A, Mohr A, Rituximab in combination with Fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23(4):694-704
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Weaver R, Alkuzweny B, Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22(23):4711-6
   PubMed Web of Science ®Google Scholar
• van Besien K, Loberiza FR, Jr., Bajorunaite R, Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102(10):3521-9
   PubMed Web of Science ®Google Scholar
• Young RC, Longo DL, Glatstein E. Watchful-waiting vs. aggressive combined modality therapy (Rx) in the treatment of stage III-IV indolent non-Hodgkin's lymphoma [abstract 790]. Proc Am Soc Clin Oncol 1987;6:200
   Google Scholar
• Czuczman M. Controversies in follicular lymphoma: “Who, what, When, Where, and Why?” (not necessarily in that order!). Hematology 2006:303-10
   PubMedGoogle Scholar
• Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13:5271
   PubMed Web of Science ®Google Scholar
• Gordon J, Millsum MJ, Guy GR, Ledbetter JA. Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen. A comparison with IL-4-mediated signaling. J Immunol 1988;140:1425-30
   PubMed Web of Science ®Google Scholar
• Goldstein MD, Watts TH. Identification of distinct domains in CD40 involved in B7-1 induction or growth inhibition. J Immunol 1996;157:2837-43
   PubMed Web of Science ®Google Scholar
• Nakajima A, Kodama T, Morimoto S, Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 1998;161:1901-07
   PubMed Web of Science ®Google Scholar
• Bergamo A, Bataille R, Pellat-Deceunynck C. CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 1997;97:652-55
   PubMed Web of Science ®Google Scholar
• Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203-9
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Schultze JL, Shahsafaei A, In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997;90:4297-306
   PubMed Web of Science ®Google Scholar
• Vyth-Dreese FA, Boot H, Dellemijn TA, Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998;94:580-6
   PubMed Web of Science ®Google Scholar
• Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999; 11:203-10
   PubMed Web of Science ®Google Scholar
• Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006;212:131-48
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF, A new member of the immunoglobulin superfamily–CTLA-4. Nature 1987;328:267-70
   PubMed Web of Science ®Google Scholar
• Girvin AM, Dal Canto MC, Rhee L, A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol 2000;164:136-43
   PubMed Web of Science ®Google Scholar
• Mathur M, Herrmann K, Qin Y, CD28 interactions with either CD80 or CD86 are sufficient to induce allergic airway inflammation in mice. Am J Respir Cell Mol Biol 1999;21:498-509
   PubMed Web of Science ®Google Scholar
• Oliveira-dos-Santos AJ, Ho A, Tada Y, CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis. J Immunol 1999;162:4490-5
   PubMed Web of Science ®Google Scholar
• Tada Y, Nagasawa K, Ho A, Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. J Immunol 1999;163:3153-9
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-8
   PubMed Web of Science ®Google Scholar
• Suvas S, Singh V, Sahdev S, Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem. 2002; 277:7766-75
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Fallarino F, Uyttenhove C, Boon T. J Immunol 1996;156:2909-17
   PubMed Web of Science ®Google Scholar
• Schattner EJ, Elkon KB, Yoo DH, J Exp Med 1995;182:1557-65
   PubMed Web of Science ®Google Scholar
• Munro JM, Freedman AS, Aster JC, In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994;83:793-98
   PubMed Web of Science ®Google Scholar
• Dogan A, Du MQ, Aiello A, Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998;91:4708-14
   PubMed Web of Science ®Google Scholar
• Younes A, Hariharan K, Allen RS, Leigh BR. Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma 2003;3:257-59
   PubMedGoogle Scholar
• Hariharan HK, Berquist LG, Murphy T, Therapeutic application of an anti-CD80 antibody (IDEC-114) in B-cell lymphoma. J Immunother 2002;25:S31
   Google Scholar
• Hariharan HK, Berquist LG, Murphy TE. Anti-CD80 antibody antibody (IDEC-114) therapy for non-Hodgkin's lymphoma [abstract 287]. Ann of Oncol 2002;13(Suppl 2):84
   PubMedGoogle Scholar
• Hariharan K, Anderson D, Leigh B, Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan) in B-cell lymphoma [abstract 2549]. Blood 2001;98:608a
   Google Scholar
• Gottlieb AB, Lebwohl M, Totoritis MC, Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol 2002;47:692-700
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kang S, Linden KG, Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004;111:28-37
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Thall A, Witzig TE, Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8
   PubMed Web of Science ®Google Scholar
• Leonard JP, Friedberg JW, Younes A, A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Younes A, Fisher D, Durable responses in patients treated with galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: long term follow-up of a phase II clinical trial. ASH 2008 Abstract # 1004
   Google Scholar
• Czuczman MS, Johnson JL, Jung SH, Cheson BD. A phase II trial of extended induction of galiximab [G] (anti-CD80 monoclonal antibody) plus rituximab [R] in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402. 10th International Conference on Malignant Lymphoma. Lugano, Switzerland 2008
   Google Scholar
• Czuczman MS, Johnson J, Jung S, A phase II trial of extended induction galiximab (anti-CD80 monoclonal antibody) plus rituximab in previously untreated follicular lymphoma: initial report of CALGB 50402 [abstract 143]. Ann Oncology 2008;19(Suppl 4):iv130
   Google Scholar
• Forstpointner R, Dreyling M. Rituximab maintenance therapy in follicular lymphoma: Curr Hematol Malig Rep 2007;2(4):213-18
   Google Scholar
• Delabie J, Ceuppens JL, Vandenberghe P, The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 1993;82:2845-52
   PubMed Web of Science ®Google Scholar
• Nozawa Y, Wakasa H, Abe M. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int 1998; 48:10-4
   PubMed Web of Science ®Google Scholar
• Galiximab in treating patients with relapsed or refractory Hodgkin's lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT00516217?term=00516217&rank=1
   Google Scholar